By Colin Kellaher
Baxter International said it weighing the potential impact of the Trump administration's planned tariffs on the medical-products maker's guidance.
Baxter on Monday said it stands by its 2025 goals of 4% to 5% operational sales growth and roughly 16.5% adjusted operating margin, but it noted that the margin guidance doesn't include any impact from the tariffs on imports from Mexico, Canada and China.
The Deerfield, Ill., company said it is working to quantify the expected impact of the tariffs and to identify potential mitigation opportunities, adding that it will provide an update during its fourth-quarter earnings conference call, which it has postponed to Feb. 20 from Feb. 13.
Baxter, which also on Monday announced the departure of Chairman and Chief Executive Jose Almeida, said it expects its fourth-quarter and full-year 2024 results will be in line with the guidance it provided in November.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 03, 2025 08:08 ET (13:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.